Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H13ClN2O |
Molecular Weight | 284.74 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C3=CC=CC=C3
InChI
InChIKey=AAOVKJBEBIDNHE-UHFFFAOYSA-N
InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3
Molecular Formula | C16H13ClN2O |
Molecular Weight | 284.74 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24552479
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24552479
Diazepam is a benzodiazepine first discovered at Hoffman-La Roche in the late 1950s. Diazepam was approved by FDA for the treatment of anxiety disorders as well as for such conditions as skeletal muscle spasm, alcohol withdrawal syndrom and convulsions (under the most known brand Valium). The drug acts by binding to GABA-A receptors and potentiating GABA evoked current. Chronic diazepam use is associated with tolerance, dependence, and withdrawal.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24007886
Curator's Comment: # Hoffmann-La Roche
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2109243 |
8.6 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VALIUM Approved UseValium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. Launch Date1963 |
|||
Palliative | VALIUM Approved UseValium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. Launch Date1963 |
|||
Palliative | VALIUM Approved UseValium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. Launch Date1963 |
|||
Palliative | VALIUM Approved UseValium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. Launch Date1963 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
208 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01417078 |
20 mg single, intranasal dose: 20 mg route of administration: intranasal experiment type: single co-administered: |
DIAZEPAM plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1505149 |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
172 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1505149 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
317 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1505149 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1227 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01417078 |
20 mg single, intranasal dose: 20 mg route of administration: intranasal experiment type: single co-administered: |
DIAZEPAM plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
330 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1505149 |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
779 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1505149 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1530 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1505149 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
48 h |
unknown, oral |
DIAZEPAM plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
unknown, oral |
DIAZEPAM plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2000 mg single, oral Overdose |
healthy, 28 years |
|
500 mg single, oral Overdose |
unhealthy, 61 years |
|
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Other AEs: Respiratory depression, Abuse... Other AEs: Respiratory depression (serious|grade 5) Sources: Abuse (serious|grade 5) |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Disc. AE: Somnolence, Hypoventilation... AEs leading to discontinuation/dose reduction: Somnolence (3 patients) Sources: Hypoventilation (2 patients) Rash (2 patients) Asthenia (1 patient) Hyperkinesia (1 patient) Incoordination (1 patient) Vasodilatation (1 patient) Urticaria (1 patient) |
10 mg 2 times / day multiple, intranasal Recommended Dose: 10 mg, 2 times / day Route: intranasal Route: multiple Dose: 10 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Respiratory depression... Other AEs: Respiratory depression (serious|grade 5) Sources: |
10 mg 4 times / day multiple, intramuscular Recommended Dose: 10 mg, 4 times / day Route: intramuscular Route: multiple Dose: 10 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Respiratory depression, Abuse... Other AEs: Respiratory depression (serious|grade 5) Sources: Abuse (serious|grade 5) |
10 mg 4 times / day multiple, oral Recommended Dose: 10 mg, 4 times / day Route: oral Route: multiple Dose: 10 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Respiratory depression... Other AEs: Respiratory depression (serious|grade 5) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abuse | serious|grade 5 | 0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Respiratory depression | serious|grade 5 | 0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Asthenia | 1 patient Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Hyperkinesia | 1 patient Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Incoordination | 1 patient Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Urticaria | 1 patient Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Vasodilatation | 1 patient Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Hypoventilation | 2 patients Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Rash | 2 patients Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Somnolence | 3 patients Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Respiratory depression | serious|grade 5 | 10 mg 2 times / day multiple, intranasal Recommended Dose: 10 mg, 2 times / day Route: intranasal Route: multiple Dose: 10 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Abuse | serious|grade 5 | 10 mg 4 times / day multiple, intramuscular Recommended Dose: 10 mg, 4 times / day Route: intramuscular Route: multiple Dose: 10 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Respiratory depression | serious|grade 5 | 10 mg 4 times / day multiple, intramuscular Recommended Dose: 10 mg, 4 times / day Route: intramuscular Route: multiple Dose: 10 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Respiratory depression | serious|grade 5 | 10 mg 4 times / day multiple, oral Recommended Dose: 10 mg, 4 times / day Route: oral Route: multiple Dose: 10 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020648_S002_DIASTAT_AP.pdf#page=8 Page: 8.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020648_S002_DIASTAT_AP.pdf#page=8 Page: 8.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020648_S002_DIASTAT_AP.pdf#page=8 Page: 8.0 |
no | |||
Page: 1.0 |
strong [IC50 2 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
major | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020648_S002_DIASTAT_AP.pdf#page=8 Page: 8.0 |
major | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020648_S002_DIASTAT_AP.pdf#page=8 Page: 8.0 |
major | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
major | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Letter: Clonazepam in the treatment of drug-induced dyskinesia. | 1975 Feb 1 |
|
[The mechanism of the anticonvulsive action of diazepam]. | 1975 Mar |
|
Tetany, tetanus or drug reaction? A case report. | 1976 Jul |
|
Favourable prognosis of prolonged coma associated with large doses of diazepam in severe tetanus. | 1976 Sep |
|
Influence of adenosine agonists and antiepileptic drugs on theophylline-induced seizures in rats. | 1998 Oct |
|
[A case of cardiac arrest after torsades de pointes due to prolonged QT interval syndrome possibly associated with subarachnoid hemorrhage]. | 1999 Jun |
|
A fugue-like state associated with diazepam use. | 1999 Jun |
|
Effects of diazepam on extracellular brain neurotransmitters in pilocarpine-induced seizures in rats. | 1999 Jun 4 |
|
Involvement of nitric oxide and nitric oxide synthase activity in anticonvulsive action. | 1999 Mar 1 |
|
Anticonvulsants for soman-induced seizure activity. | 1999 Mar-Apr |
|
Etomidate-induced convulsion prior to electroconvulsive therapy. | 2000 Oct |
|
[Potentiation of local anesthesia in endonasal surgery]. | 2001 |
|
Negative inotropic effect of diazepam in isolated guinea pig heart. | 2001 Feb |
|
[Prevention of postoperative nausea and vomiting in gynecologic surgery with 3 fixed doses of metoclopramide, droperidol or placebo]. | 2001 Feb |
|
Extracellular serotonin is enhanced in the striatum, but not in the dorsal hippocampus or prefrontal cortex, in rats subjected to an operant conflict procedure. | 2001 Feb |
|
Molecular modeling and QSAR analysis of the interaction of flavone derivatives with the benzodiazepine binding site of the GABA(A) receptor complex. | 2001 Feb |
|
Lack of reinforcing effect of the benzodiazepine and tricyclic antidepressant combination of diazepam and dothiepin. | 2001 Feb |
|
[Febrile convulsions, Treatment and prognosis]. | 2001 Feb 19 |
|
[Anesthesia for a patient with cardiac sarcoidosis]. | 2001 Jan |
|
Development of differential tolerance to the sedative and anti-stress effects of benzodiazepines. | 2001 Jan |
|
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice. | 2001 Jan |
|
[Effect of diazepam on apnea attacks in a 6-year-old girl with Rett syndrome: a polysomnographic study]. | 2001 Jan |
|
Radial entrapment neuropathy due to chronic injection-induced triceps fibrosis. | 2001 Jan |
|
The octadecaneuropeptide ODN stimulates neurosteroid biosynthesis through activation of central-type benzodiazepine receptors. | 2001 Jan |
|
Thiopentone induction dose requirement in dogs is little influenced by co-administration of diazepam or prior treatment with phenobarbitone or corticosteroids, but is reduced in the presence of brain pathology. | 2001 Jan |
|
Evaluating the use of benzodiazepines following recent bereavement. | 2001 Jan |
|
The efficacy of oral clonidine premedication in the prevention of postoperative vomiting in children following strabismus surgery. | 2001 Jan |
|
Long-term reduction of benzodiazepine receptor density in the rat cerebellum by acute seizures and kindling and its recovery 6 months later by a pentylenetetrazole challenge. | 2001 Jan 12 |
|
Intranasal midazolam for treating febrile seizures in children. Buccal midazolam for childhood seizures at home preferred to rectal diazepam. | 2001 Jan 13 |
|
Simple and sensitive high-performance liquid chromatographic method for the determination of 1,5-benzodiazepine clobazam and its active metabolite N-desmethylclobazam in human serum and urine with application to 1,4-benzodiazepines analysis. | 2001 Jan 5 |
|
Brain-derived neurotrophic factor superinduction parallels anti-epileptic--neuroprotective treatment in the pilocarpine epilepsy model. | 2001 Mar |
|
[3H]Ro 15-1788 binding sites to brain membrane of the saltwater Mugil cephalus. | 2001 Mar |
|
Topical anesthesia for cataract surgery: a population-based perspective. | 2001 Mar |
|
Molecular targets for the myorelaxant action of diazepam. | 2001 Mar |
|
Pharmacological evidence for a role of gamma-aminobutyric acid A receptor mechanism in modulating nitric oxide synthase activity in rat brain. | 2001 Mar |
|
Trimethylolpropane phosphate induces epileptiform discharges in the CA1 region of the rat hippocampus. | 2001 Mar 1 |
|
A behavioral economic analysis of polydrug abuse in alcoholics: asymmetrical substitution of alcohol and cocaine. | 2001 Mar 1 |
|
Evidence for a common binding cavity for three general anesthetics within the GABAA receptor. | 2001 Mar 15 |
|
Female gastrin-releasing peptide receptor (GRP-R)-deficient mice exhibit altered social preference for male conspecifics: implications for GRP/GRP-R modulation of GABAergic function. | 2001 Mar 16 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:44:35 GMT 2025
by
admin
on
Wed Apr 02 08:44:35 GMT 2025
|
Record UNII |
Q3JTX2Q7TU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000007542
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
FDA ORPHAN DRUG |
384112
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
EPA PESTICIDE CODE |
600069
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
FDA ORPHAN DRUG |
334911
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
FDA ORPHAN DRUG |
518316
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.4
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
LIVERTOX |
NBK548352
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
WHO-VATC |
QN05BA01
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
FDA ORPHAN DRUG |
543516
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
FDA ORPHAN DRUG |
638118
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
24.3
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
FDA ORPHAN DRUG |
382512
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
WHO-ATC |
N05BA01
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
05
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
DEA NO. |
2765
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
FDA ORPHAN DRUG |
61591
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
||
|
NDF-RT |
N0000175694
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1185008
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
m4267
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | Merck Index | ||
|
169897
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
3322
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | RxNorm | ||
|
D003975
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
3057
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
Diazepam
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
DB00829
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
DTXSID4020406
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
852
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
DIAZEPAM
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
SUB07069MIG
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
3364
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
Q3JTX2Q7TU
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
C28982
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
1295
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
439-14-5
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
3016
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
CHEMBL12
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
49575
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
207-122-5
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
100000092362
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
Q3JTX2Q7TU
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
77518
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | |||
|
DIAZEPAM
Created by
admin on Wed Apr 02 08:44:36 GMT 2025 , Edited by admin on Wed Apr 02 08:44:36 GMT 2025
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Very slightly soluble in water; soluble in ethanol (~750 g/l) TS. Category: Tranquillizer. Storage: Diazepam should be kept in a well-closed container, protected from light. Definition: Diazepam contains not less than 99.0% and not more than 101.0% of C16H13ClN2O, calculated with reference to the dried substance. |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PARENT |
|
||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE TOXIC -> PARENT |
Metabolite produces adverse autonomic nervous symptoms in man.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
pKa | CHEMICAL |
|
||||
Volume of Distribution | PHARMACOKINETIC |
|
||||
Tmax | PHARMACOKINETIC |
|
IV: 8 minutes |
|
||
PROTEIN BINDING | PHARMACOKINETIC |
|
||||
Biological Half-life | PHARMACOKINETIC |
|
IV: 15-21 HOURS (CHILD 2-12 YEARS) |
|||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
SEDATION, ENDOSCOPIC PROCEDURE: 20 mg IV IMMEDIATELY PRIOR TO PROCEDURE |
|
||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
BIOAVAILABILTY | PHARMACOKINETIC |
|
|
|||